Evidence map›Paper›PMID 42129963›Full record

ArticleVeterinary and comparative oncology2026

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines.

Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto-Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda

Abstract read
In one paragraph

Article in Veterinary and comparative oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hiroki SakumaLaboratory of Veterinary Internal Medicine, Veterinary Clinical Science Unit, Department of Veterinary Medical Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan.ORCID https://orcid.org/0009-0008-4733-3693
Hirotaka TomiyasuLaboratory of Veterinary Internal Medicine, Veterinary Clinical Science Unit, Department of Veterinary Medical Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan.
Mari TakamiyaDrug Discovery Initiative, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan.
Yuko Goto-KoshinoLaboratory of Veterinary Internal Medicine, Veterinary Clinical Science Unit, Department of Veterinary Medical Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan.
Atsushi TsukamotoLaboratory of Laboratory Animal Science, Azabu University, Sagamihara, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-2047-4970
Makoto BonkobaraDepartment of Veterinary Clinical Pathology, Nippon Veterinary and Life Science University, Musashino, Tokyo, Japan.
Masaru OkudaLaboratory of Veterinary Internal Medicine, Veterinary Clinical Science Unit, Department of Veterinary Medical Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan.

Funding

AMED JP24ama121053Japan Science and Technology Agency JPMJSP2108Japan Society for the Promotion of Science 23K05562Japan Society for the Promotion of Science 23K23778
6 · The paper itself

Abstract

Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high throughput screening, which examined the effects of 1824 chemical compounds on the 10 CHS cell lines. Among the compounds examined, 73 compounds were identified as candidates to show antiproliferative effects in all CHS cell lines examined, and the median IC

Indexed as

Antineoplastic AgentsDog DiseasesHigh-Throughput Screening AssaysHistiocytic SarcomaAnimalsCell Line, TumorCell ProliferationDogsAntineoplastic AgentsAkt pathwaydogduvelisibmolecular‐targeted drugPI3Kγ

Identifiers

PMID42129963
PMCPMC13456615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.